PERMANENT VASCULAR ACCESS FOR HEMODIALYSIS: A MODERN VIEW
https://doi.org/10.24884/1561-6274-2013-17-6-56-70
Abstract
At the modern period of medicine using the renal replacement therapy let reach full medical and social rehabilitation of patients with end-stage renal disease. The hemodialysis is the main method of extracorporal detoxication. The successful hemodialysis therapy depends on choosing the vascular access and maintaining it good condition while all patients life. In spite of various modification of blood accesses the native arteriovenous fistula is the most preferable type of vascular access for hemodialysis. The arteriovenous grafts are at the second line. Some different cases demand individual approach to choice the vascular access. Careful using, timely monitoring and revision keep saving the access for a long time and reducing a risk of complication. It can improve the quality of life patients with ESRD.
About the Authors
S. V. Alferov
Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
S. A. Karpov
Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
K. M. Grinev
Ленинградская областная клиническая больница
Russian Federation
Russian Federation
A. N. Vasilyev
Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
References
1. Ермоленко ВМ. Хронический гемодиализ. Медицина, М., 1982; 278с
2. Kolff WJ, Berk HTh. The artificial kidney: a dialyzer with a great area. ActaMedScand1944; 117:121-134
3. Quinton WE, Dillard D, Scribner BH. Cannulation of blood vessels for prolonged hemodialysis. Trans Am Soc Artif Intern Organs 1960; 104-113
4. Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. N Engl J Med 1966; 275 (20): 1089–1092
5. Dunlop MG, Mackinlay JY, Jenkins AM. Vascular access: experience with the brachiocephalic fistula. Ann R Coll Surg Engl 1986; 68:203-206
6. Stonebridge PA, Edington D, Jenkins AM. ‘Brachial/basilic vein’ transposition forvascular access. J R Coll Surg Edinb 1995; 40:219-220
7. Bryan FA. Seventh Annual Progress ReportOct. 1, 1974 – Oct. 1, 1975 Report № AK-7-7-1387. Research Triangle Institute, Triangle Park, NC. The National Dialysis Registry – Artificial Kidneys – Chronic Uremia Program, National Institutes of Health, Bethesda, MD, 1975
8. Geis WP, Giacchino J. A game plan for vascular access for hemodialysis. Surgical Rounds 1980; 132(3):332-335
9. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicaemia in dialysis patients:incidence, risk factors and prognosis. Kidney Int 1999; 55: 1081-1090
10. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can’t live without them. Kidney Int 1999; 56: 1-17
11. U.S. Renal Data System. The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment. Am J Kidney Dis 1997; 30(Suppl.1):S160- S177
12. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis Vascular Access Morbidity. J Am Soc Nephrol 1996; 7:523-535
13. Chazan JA, London MR, Pono L. The impact of diagnosisrelated groups on the cost ofhospitalisation for end-stage renal disease patients at Rhode Island Hospital from 1987 to1990. Am J Kidney Dis 1992; 6:523-525
14. Смирнов АВ. Заместительная почечная терапия. Нефрология 2011; 15(1): 33-46
15. Енькина ТН, Лукичев БГ, Енькин АА, Гринев КМ. Влияние шунтового кровотока по артериовенозной фистуле на развитие сердечной недостаточности у больных с хронической почечной недостаточностью, корригированной программным гемодиализом. Нефрология 2000; 4(1):48-52
16. Rutherford RB. Rutherford’s vascular surgery / Cronenwett Jack L., Johnston K. Wayne; associate editors, Cambria Richard et al.7th ed. Philadelphia: Saunders Elsevier, 2010: 1169-1173
17. Wilson SE. Vascular Access. Principles and Practice / Samuel Eric Wilson. – 5th edition. Philadelphia: Lippincott Williams & Wilkins, a Wolter Kluwer business, 2010:173-174
18. NKF-DOQI clinical practice guidelines for vascular access. New York, National Kidney Foundation, 1997; 191p
19. Konner K. Primary vascular access in diabetic patients: an audit. Nephrol Dial Transplant 2000 Sep; 15(9): 1317-1325
20. Konner K, Nonnast-Daniel B, Ritz E. The Arteriovenous Fistula. Journal of the American Society of Nefrology 2003; 14: 1669-1680
21. Wixon CL, Hughes JD, Mills JL. Understending strategies for the treatment of ischemic steal syndrome after hemodialysis access. J Am Coll Surg 2000 Sept; 191(3): 301-310
22. Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001 Oct; 60(4): 1443-1451
23. Kojecky Z, Utikal P, Sekanina Z et al., Venous hypertension following average arterio-venous fistula for haemodialysis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002 Dec; 146(2):77-79
24. Marr KA, Sexton DJ, Conlon PJ et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997 Aug 15; 127(4): 275-280
25. Verghese S, Padmaja P, Sudha P et al. Central venous catheter related infections. J Commun Dis 1999 Mar; 31(1): 1-4
26. Rodriguez JA, Armadans L, Ferrer E et al. The function of permanent vascular access. Nephrol Dial Transplant 2000; 15(3):402-408
27. Chin AI, Chang W, Fitzgerald JT et al. Intra-access blood flow in patients with newly created upper-arm arteriovenous native fistulae for hemodialysis access. Am J Kidney Dis 2004;44(5):850- 858
28. Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1-27
29. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1-158
30. Gradman WS, Laub J, Cohen W. Femoral vein transposition for arteriovenous hemodialysis access: improved patient selection and intraoperative measures reduce postoperative ischemia. J Vasc Surg 2005; 41(2):279-284
31. Hurt AV, Batello-Cruz M, Skipper BJ et al. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. Am J Surg 1983; 146(6):844-847
32. Liu Z, Zhu B, Wang X et al. Clinical studies of hemodialysis access through formaldehyde-fixed arterial allografts. Kidney Int 2007; 72(10):1249-1254
33. Canaud B. Formaldehyde-fixed arterial allograft as a novel vascular access alternative in end-stage renal disease patients. Kidney Int 2007; 72(10):1179-1181
34. Hurlbert SN, Mattos MA, Henretta JP et al. Long-term patency rates, complications and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: a prospective study that compares Impra versus Gore-tex grafts. Cardiovasc Surg 1998; 6:652-656
35. Lenz BJ, Veldenz HC, Dennis JW et al. A three-year followup on standard versus thin wall ePTFE grafts for hemodialysis. J Vasc Surg 1998; 28(3):464-470
36. Schuman ES, Standage BA, Ragsdale JW, Gross GF. Reinforced versus non reinforced polytetrafluoroethylene grafts for hemodialysis access. Am J Surg 1997; 173:407
37. Miller CD, Robbin ML, Barker J, Allon M. Comparison of arteriovenous grafts in the thigh and upper extremities in hemodialysis patients. J Am Soc Nephrol 2003; 14(11):2942-2947
38. Ram SJ, Sachdeva BA, Caldito GC et al. Thigh grafts contribute significantly to patients’ time on dialysis. Clin J Am Soc Nephrol 2010; 5(7):1229-1234
39. Hessinger M, Zitta S, Holzer H, Tiesenhausen K. [Dialock® – an alternative to Permcath trade mark and Access Graft] [Article in German]. Zentralbl Chir 2003; 128 (9): 753–756
40. Metry G, Uhlin F, Almroth G. Swedish experience of the Dialock. Scand J Urol Nephrol 2007; 41 (3): 249–253
41. Moran JE, Prosl F. Totally implantable subcutaneous devices for hemodialysis access. Contrib Nephrol 2004; 142: 178–192
42. Rayan SS, Terramani TT, Weiss VJ, Chaikof EL. The LifeSite Hemodialysis Access System in patients with limited access. J Vasc Surg 2003; 38 (4): 714–718
43. Ross JR. Successful treatment of a LifeSite Hemodialysis Access System pocket infection with large-volume kanamycin solution irrigation. Adv Ren Replace Ther 2003; 10 (3): 248–253
44. Szczepanska M, Szprynger K, Stoksik P et al. [Port device central venous access in children with chronic renal disease – personal experience][Article in Polish]. Wiad Lek 2006; 59 (11–12): 814–818
45. Richard T. Hemodialysis access without a shunt or catheter: the circulating port. J Vasc Access 2007; 8 (2): 86–90
46. McAllister TN, Maruszewski M, Garrido SA et al. Effectiveness of haemodialysis access with an autologous tissueengineered vascular graft: a multicentre cohort study. Lancet 2009; 373:1440-1446
47. Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299(18):2164-2171
48. Kaufman JL, Garb JL, Berman JA et al. A prospective comparison of two expanded polytetrafluoroethylene grafts for linear forearm hemodialysis access: does the manufacturer matter? J Am Coll Surg 1997; 185(1):74-79
49. Polo JR, Tejedor A, Polo J et al. Long-term follow-up of 6-8 mm brachioaxillary polytetrafluorethylene grafts for hemodialysis. Artif Organs 1995; 19(11):1181-1184
50. Sands J, Miranda CL. Increasing numbers of AV fistulas for hemodialysis access. Clin Nephrol 1997; 48(2):114-117
51. Miller PE, Tolwani A, Luscy CP et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int 1999; 56(1):275-280
52. Lockhart ME, Robbin ML, McNamara MM, Allon M. Association of pelvic arterial calcification with arteriovenous thigh graft failure in haemodialysis patients. Nephrol Dial Transplant 2004; 19(10):2564-2569
53. Lok CE, Allon M, Moist L et al. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol 2006; 17(11):3204-3212
54. Huijbregts HJ, Bots ML, Wittens CH et al. Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 2008; 3:714-719
55. Silva MB Jr, Hobson RW 2nd, Pappas PJ et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg 1998; 27(2):302-307
56. Miller CD, Robbin ML, Allon M. Gender differences in outcomes of arteriovenous fistulas in hemodialysis patients. Kidney Int 2003; 63:346-352
57. Obialo CI, Tagoe AT, Martin PC, Asche-Crowe PE. Adequacy and survival of autogenous arteriovenous fistula in African American hemodialysis patients. ASAIO J 2003; 49:435-439
58. Segal JH, Kayler LK, Henke P et al. Vascular access outcomes using the transposed basilic vein arteriovenous fistula. Am J Kidney Dis 2003; 42(1):151-157
59. Ravani P, Brunori G, Mandolfo S et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol 2004; 15(1):204-209
60. van der Linden J, Lameris TW, van den Meiracker AH et al. Forearm venous distensibility predicts successful arteriovenous fistula. Am J Kidney Dis 2006; 47(6):1013-1019
61. Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J Am Soc Nephrol 2007; 18(6):1936-1941
62. Beathard GA, Settle SM, Shields MW. Salvage of the nonfunctioning arteriovenous fistula. Am J Kidney Dis 1999; 33(5):910-916
63. Konner K, Hulbert-Shearon TE, Roys EC, Port FK. Tailoring the initial vascular access for dialysis patients. Kidney Int 2002; 62(1):329-338
64. Faiyaz R, Abreo K, Zaman F et al. Salvage of poorly developed arteriovenous fistulae with percutaneous ligation of accessory veins. Am J Kidney Dis 2002; 39:824-827
65. Falk A, Teodorescu V, Lou WY et al. Treatment of “swing point stenoses” in hemodialysis arteriovenous fistulae. Clin Nephrol 2003; 60(1):35-41
66. Beathard GA, Arnold P, Jackson J et al. Aggressive treatment of early fistula failure. Kidney Int 2003; 64(4):1487-1494
67. Nassar GM, Nguyen B, Rhee E, Achkar K. Endovascular treatment of the “failing to mature” arteriovenous fistula. Clin J Am Soc Nephrol 2006; 1(2):275-280
68. Sottiurai VS, Stephens A, Champagne L et al. Comparative results of early and delayed cannulation of arteriovenous graft in haemodialysis. Eur J Vasc Endovasc Surg 1997; 13:139-141
69. Rayner HC, Pisoni RL, Gillespie BWet al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63(1):323-330
70. Brunori G, Ravani P, Mandolfo S et al. Fistula maturation: doesn’t time matter at all? Nephrol Dial Transplant 2005; 20(4):684-687
71. Saran R, Dykstra DM, Pisoni RL et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19(9):2334-2340
72. Saran R, Pisoni RL, Young EW. Timing of first cannulation of arteriovenous fistula: are we waiting too long? Nephrol Dial Transplant 2005; 20(4):688-690
73. Bonalumi U, Civalleri D, Rovida S et al. Nine years’ experience with end-to-end arteriovenous fistula at the ‘anatomical snuff box’ for maintenance haemodialysis. Br J Surg 1982; 69:486-488
74. Munda R, First MR, Alexander JW et al. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983; 249(2):219-222
75. Young EW, Dykstra DM, Goodkin DA et al. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002; 61(6):2266-2271
76. Bender MH, Bruyninckx CM, Gerlag PG. The brachiocephalic elbow fistula: a useful alternative angioaccess for permanent hemodialysis. J Vasc Surg 1994; 20:808-813
77. Hodges TC, Fillinger MF, Zwolak RM, et al. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg 1997; 26(6):1009-1019
78. Coburn MC, Carney WI Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc Surg 1994; 20(6):896-902
79. Iwashima Y, Horio T, Takami Y et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974-982
80. Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am J Nephrol 1998; 18(5):379-383
81. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37:S137-181
82. Tesio F, De Baz H, Panarello G et al. Double catheterization of the internal jugular vein for hemodialysis: indications, techniques, and clinical results. Artif Organs 1994; 18(4):301-304
83. Saad TF. Bacteriemia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34(6):1114-1124
84. Suhocki PV, Conlon PJ Jr, Knelson MH et al. Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis 1996; 28:379-386
85. Atherikul K, Schwab SJ, Conlon PJ. Adequacy of haemodialysis with cuffed central-vein catheters. Nephrol Dial Transplant 1998; 13:745-749
86. Dunn J, Nylander W, Richie R. Central venous dialysis access: experience with a dual-lumen, silicone rubber catheter. Surgery 1987; 102(5):784-789
87. Oliver MJ, Mendelssohn DC, Quinn RR et al. Catheter potency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol 2007; 2(6):1201-1206
88. Oliver MJ, Rothwell DM, Fung K et al. Late creation of vascular access for hemodialysis and increased risk of sepsis. J Am Soc Nephrol 2004; 15(7):1936-1942
89. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62(2):620-626
90. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis 2003; 42(5):1013-1019
91. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15(2):477-486
92. Thomson PC, Stirling CM, Geddes CC, et al. Vascular access in haemodialysis patients: a modifiable risk factor for bacteremia and death. QJM 2007; 100(7):415-422
93. Pisoni RL, Arrington CJ, Albert JM et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 2009; 53:475-491
94. Astor BC, Eustace JA, Powe NR et al. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 2005; 16(5):1449-1455
95. Allon M, Daugirdas J, Depner TA et al. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis 2006; 47(3):469-477
96. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62(4):1109-1124
97. Lok CE, Oliver MJ. Overcoming barriers to arteriovenous fistula creation and use. Semin Dial 2003; 16(3):189-196
98. Yigla M, Nakhoul F, Sabag A et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123: 1577-1582
99. Nakhoul F, Yigla M, Gilman R et al. The pathogenesis of pulmonary hypertension in haemodialysis patients via arteriovenous access. Nephrol Dial Transplant 2005; 20: 1686-1692
Review
For citations:
Alferov S.V., Karpov S.A., Grinev K.M., Vasilyev A.N. PERMANENT VASCULAR ACCESS FOR HEMODIALYSIS: A MODERN VIEW. Nephrology (Saint-Petersburg). 2013;17(6):56-70. (In Russ.) https://doi.org/10.24884/1561-6274-2013-17-6-56-70
Views:
952
Email this article 